1. Show article details.

    Biogen scraps two late-stage trials for Alzheimer's treatment

    Reuters – 12:09 PM ET 09/13/2019

    Biogen Inc (BIIB) and Eisai Co Ltd (ESALF) are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease.

  2. Show article details.

    Purdue OxyContin settlement would rank among largest in pharma history

    Reuters – 3:35 PM ET 09/11/2019

    OxyContin maker Purdue Pharma LP has reached a tentative multibillion-dollar agreement with some plaintiffs aimed at settling thousands of lawsuits over its alleged role in the U.S. opioid crisis, Reuters reported on Wednesday, citing people familiar with the matter.

  3. Show article details.

    Neurotrope shares crash after Alzheimer's drug fails in trial

    Reuters – 9:20 AM ET 09/09/2019

    Drug developer Neurotrope Inc's (NTRP) shares tumbled nearly 80% on Monday after the company said its experimental treatment for Alzheimer's disease did not meet the main goal of a mid-stage study. This is the second time in just over two years that the treatment - Bryostatin-1 - failed to meet its targets, raising questions about the drug's future.

  4. Show article details.

    US STOCKS-Wall Street set to open higher on hopes of monetary stimulus

    Reuters – 9:17 AM ET 09/09/2019

    * Futures up: Dow 0.23%, S&P 0.34%, Nasdaq 0.29% By Uday Sampath Kumar. U.S. stocks were set to open higher on Monday, as mixed global economic data lifted expectations of monetary stimulus from central banks, including the U.S. Federal Reserve.

  5. Show article details.

    Slovakian biotech firm signals tentative Alzheimer's drug hope

    Reuters – 5:46 AM ET 09/09/2019

    An Alzheimer's vaccine developed by a privately held Slovakian biotech firm showed early signs of efficacy in a mid-stage trial, a rare step forward in the fight against the brain-wasting disease, the company said on Monday.

  6. Show article details.

    BRIEF-Eli Lilly Says To Submit New Drug Application For Selpercatinib By Year-End

    Reuters – 3:58 AM ET 09/09/2019

    Eli Lilly and Co (LLY): * LILLY ANNOUNCES POSITIVE RESULTS FOR SELPERCATINIB, DEMONSTRATING A 68 PERCENT OBJECTIVE RESPONSE RATE AND SUSTAINED DURABILITY IN HEAVILY PRETREATED RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER. * NEW DRUG APPLICATION TO BE SUBMITTED BY YEAR-END FOR SELPERCATINIB Source text for Eikon: Further company coverage:

  7. Show article details.

    Lilly's targeted RET drug shrinks tumors in lung cancer trial

    Reuters – 3:20 AM ET 09/09/2019

    Eli Lilly and Co's LOXO-292, a experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.

  8. Show article details.

    Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer

    PR Newswire – 3:20 AM ET 09/09/2019

    INDIANAPOLIS, Sept. 9, 2019 Eli Lilly and Company (LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known as LOXO-292, for the treatment of RET fusion-positive non-small cell lung cancer.

  9. Show article details.

    Drugmakers file second court challenge to Canada's new drug price rules

    Reuters – 1:00 PM ET 09/06/2019

    Canada's main pharmaceutical industry lobby group, along with 16 of its member companies, filed a lawsuit on Friday to block new regulations meant to lower patented drug prices, the second legal challenge to a new regime that could eventually reduce prices in the United States as well.

  10. Show article details.

    Novo Nordisk to cut insulin prices in the U.S.

    Reuters – 9:14 AM ET 09/06/2019

    Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly (LLY). President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder".

  11. Show article details.

    Novo Nordisk to cut insulin prices for some U.S. diabetics

    Reuters – 8:18 AM ET 09/06/2019

    Novo Nordisk said on Friday it would offer cheaper insulin to some U.S. diabetics in response to intense criticism over the high price of the medication and following similar moves by rivals Sanofi and Eli Lilly.

  12. Show article details.

    Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'

    Reuters – 2:04 AM ET 09/06/2019

    - In the halls of MD Anderson Cancer Center, the drug Vitrakvi is known for having a "Lazarus effect" in some patients because it can reverse late-stage cancer that has defied all other treatment options.

  13. Show article details.

    INSIGHT-Inside drugmakers' strategy to boost cancer medicines with "Lazarus effect"

    Reuters – 1:00 AM ET 09/06/2019

    In the halls of MD Anderson Cancer Center, the drug Vitrakvi is known for having a "Lazarus effect" in some patients because it can reverse late-stage cancer that has defied all other treatment options.

  14. Show article details.

    Lilly's Pain Clinical Trial Protocol Selected for FDA Complex Innovative Trial Designs Pilot Meeting Program

    PR Newswire – 3:00 PM ET 09/05/2019

    INDIANAPOLIS, Sept. 5, 2019  Eli Lilly and Company (LLY) today announced the U.S. Food and Drug Administration has accepted its application to enter the Complex Innovative Trial Designs Pilot Meeting Program, an initiative which aims to further modernize drug development, improve efficiency, and promote innovation.

  15. Show article details.

    Lilly to Participate in Morgan Stanley Global Healthcare Conference

    PR Newswire – 4:15 PM ET 09/04/2019

    INDIANAPOLIS, Sept. 4, 2019  Eli Lilly and Company (LLY) will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laboratories, will participate in a fireside chat at 1:00 p.m., Eastern Time.

  16. Show article details.

    China expands drug bulk-buy programme, puts pressure on pharma firms

    Reuters – 4:56 AM ET 09/02/2019

    China has expanded a pilot drug bulk-buying programme to almost the entire country in an attempt to negotiate lower prices from drug manufacturers, heaping fresh pressure on multinational pharmaceutical companies and their domestic rivals. The programme rolled out last year saw 11 Chinese cities, including Beijing and Shanghai, band together behind a tender process to bulk-buy 25 types of drugs.

  17. Show article details.

    U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta

    Reuters – 5:00 PM ET 08/29/2019

    The U.S. Food and Drug Administration on Thursday granted Mylan NV (MYL) tentative approval for its generic version of Eli Lilly and Co's (LLY) lung cancer drug Alimta. Shares of Mylan closed up 3.9% at $19.90 on Thursday. A tentative approval generally signals that the FDA has signed off on the company's marketing application, but that it cannot sell the medicine until the U.S. patents have expired.

  18. Show article details.

    U.S. FDA gives fast track status to AstraZeneca's diabetes drug Farxiga

    Reuters – 2:55 AM ET 08/27/2019

    AstraZeneca Plc (AZN) said on Tuesday that the U.S. Food and Drug Administration has granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.

  19. Show article details.

    BRIEF-Eli Lilly Says U.S. FDA Approved Taltz Injection 80 Mg/Ml For Treatment Of Adults With Active Ankylosing Spondylitis

    Reuters – 6:47 AM ET 08/26/2019

    Eli Lilly and Co (LLY): * LILLY RECEIVES U.S. FDA APPROVAL FOR TALTZ FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS. * ELI LILLY SAYS U.S. FDA APPROVED TALTZ INJECTION 80 MG/ML FOR TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS. * ELI LILLY SAYS SAFETY PROFILE OBSERVED IN PATIENTS WITH AS TREATED WITH TALTZ IS CONSISTENT WITH SAFETY PROFILE IN PATIENTS WITH PSORIASIS.

  20. Show article details.

    Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

    PR Newswire – 6:45 AM ET 08/26/2019

    INDIANAPOLIS, Aug. 26, 2019 Eli Lilly and Company (LLY) announced today that the U.S. Food and Drug Administration has approved Taltz® injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis, also known as radiographic axial spondyloarthritis.

Page:

Today's and Upcoming Events

  • Oct
    23

    LLY to announce Q3 earnings (Confirmed)

Past Events (last 90 days)

  • Aug
    14

    LLY ex-Dividend for $0.65 on 08/14/2019

    • Announce Date: 06/19/2019
    • Record Date: 08/15/2019
    • Pay Date: 09/10/2019
  • Jul
    30

    LLY announced Q2 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.